Frédérique Zindy

St. Jude Children's Research Hospital — United States

Medicine · Health Sciences

45h-index12.6kcitations134works1.42yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Publications134 total

Supplementary Table S1 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2025Open Access

Supplementary Table S4 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2025Open Access

Supplementary Table S2 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2025Open Access

Supplementary Methods, Figures and Tables from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2025Open Access

EXTH-20. Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target

Neuro-Oncology·2025

Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target

1 cited

Cancer Cell·2025· 1 citedOpen Access

TMOD-19. GERMLINEELP1 DEFICIENCY SENSITIZES CEREBELLAR GRANULE NEURON PROGENITORS TO SHH MEDULLOBLASTOMA

Neuro-Oncology·2024Open Access

MDB-13. GERMLINEELP1 DEFICIENCY SENSITIZES CEREBELLAR GRANULE NEURON PROGENITORS TO SHH MEDULLOBLASTOMA

Neuro-Oncology·2024Open Access

Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models

13 cited

Journal of Clinical Investigation·2024· 13 citedOpen Access

Data from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2024Open Access

250 Manipulating T cell epigenetic programs to improve persistence against group 3 pediatric medulloblastoma

Regular and Young Investigator Award Abstracts·2023Open Access

MDB-20. IMPROVING THE PERSISTENCE OF CAR T CELLS AGAINST GROUP 3 MEDULLOBLASTOMAS VIA EPIGENETIC REGULATION OF EXHAUSTION

Neuro-Oncology·2023Open Access

Scaffold protein Scribble is a potent modulator of Sonic Hedgehog signaling

Journal of Pharmacology and Experimental Therapeutics·2023Open Access

Supplementary Methods, Figures and Tables from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2023Open Access

Supplementary Table S2 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2023Open Access

Supplementary Table S1 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2023Open Access

Data from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2023Open Access

Supplementary Table S1 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2023Open Access

Supplementary Table S4 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2023Open Access

Supplementary Table S2 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

2023Open Access

page 1 of 7Next →

Frequent Co-authors

Martine F. Roussel(34), Charles J. Sherr(24), Jerold E. Rehg(9), Olivier Ayrault(8), Richard J. Gilbertson(5), Takehiko Kamijo(4), Peter J. McKinnon(4), Eugénia Lamas(4), Richard J. Smeyne(4), Stephen X. Skapek(4), David H. Randle(3), John L. Cleveland(3), David Finkelstein(3), Youngsoo Lee(3), Amar Gajjar(3), Christian Bréchot(3), Justine J. Cunningham(3), Christopher Calabrese(3), Dawn E. Quelle(2), Richard A. Ashmun(2)